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Rac1 and Cdc42 are members of the Rho family of small GTPases and have been shown to induce lamellipodia and filopodia formation,
respectively. This leads to changes in cytoskeleton organization and as a consequence affects cell migration. In the present work we demonstrate that
endogenous Rac1 and Cdc42 interact with calmodulin (CaM) in a Ca2+-dependent fashion. The interaction of Rac1 and Cdc42 with CaMwas shown
to be direct. This novel interaction was further confirmed in platelets using co-immunoprecipitation studies. Using CaM database analysis and in vitro
peptide competition assays we have identified a 14 amino acid region in Rac1 that is essential for CaMbinding. The scrambled form of the peptide did
not bind CaM demonstrating specificity of the predicted CaM binding region in Rac1. A similar region capable of binding CaM exists in Cdc42.
Furthermore, using the optimal activation time-point for each GTPase, the role of CaM in the function of Rac1 and Cdc42 was examined. Results
demonstrate that in human platelets, thrombin caused maximal activation of Rac1 and Cdc42 at ~60 s and ~25 s respectively. The potent CaM
antagonist W7 abolished thrombin-mediated activation of Rac1. However, addition of W7 resulted in the activation of Cdc42 over basal andW7 did
not inhibit thrombin-mediated activation of Cdc42. The less potent CaM inhibitor, W5, did not have any effect on Rac1 and Cdc42 activation. The
results demonstrate that in platelets, binding of CaM to Rac1 increases its activation while its binding to Cdc42 reduces the activation of this GTPase.
This suggests an important role for CaM in coordinating Rac1 and Cdc42 activation and in the regulation of cytoskeleton remodeling.
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Rac1 and Cdc42 are members of the Rho family of small
GTP-binding proteins that have been found to play an essential
role in cytoskeleton remodeling [1–3]. Rac1 induces membrane
ruffling, chemotaxis, and lamellipodia formationwhereas Cdc42
is involved in filopodia formation [4,5]. Rac1 and Cdc42 pro-Abbreviations: Calmodulin, CaM; SDS, sodium dodecyl sulfate; PAGE,
polyacrylamide gel electrophoresis; PVDF, polyvinylidene difluoride; GST,
glutathione S-transferase; Pak1, p21-activated kinase; PMSF, phenylmethylsul-
fonyl fluoride; AEBSF, 4-[(2-aminoethyl)]-benzenesulfonyl fluoride; EGTA,
Ethylene glycol-bis (2-aminoethyl ether)-N,N,N′,N′)-tetraacetic acid; GEF,
guanine nucleotide exchange factor
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doi:10.1016/j.bbamcr.2008.01.022teins cycle between the active GTP-bound form and inactive
GDP-bound form [1,4,6]. This cycling is controlled by guanine
nucleotide exchange factors (GEFs). Inactivation is mediated by
GTPase-activating proteins (GAPs), which accelerate the rate of
hydrolysis of bound GTP to GDP.
In addition to their role in cytoskeleton remodeling, Rac1 and
Cdc42 are also involved in regulating gene expression via acti-
vation of kinases leading to enhanced activity of stress-activated
protein kinases (SPAKs), including JNK and p38 MAP kinases
[7–11], Janus kinase (Jaks) and phosphorylation of signal trans-
ducers and activators of transcription (STATs) [8,9,12]. The
inactivation of Cdc42 using gene-targeted mutations in mouse
embryonic stem (ES) and mouse germ line cells has de-
monstrated that Cdc42-deficient ES cells exhibit normal
proliferation and phosphorylation of mitogen- and stress-
activated protein kinases. However, Cdc42 deficiency caused
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zation in ES cells [13].
Ca2+ ions are an important secondary messenger in a variety
of cellular signaling pathways [14]. Majority of the effects of
Ca2+ in the cell are mediated through proteins that bind calcium.
Calmodulin (CaM), a major calcium (Ca2+) sensor, is a highly
conserved 17 kDa ubiquitous eukaryotic protein that in response
to changes in intracellular Ca2+ levels binds to over 100 different
targets in the cell including, serine/threonine kinases [15]. CaM
has a unique structure consisting of two globular domains each
containing a pair of EF-hand motifs that are connected by a
central helix [15,16]. The α-helical structure within these two
domains opens upon calcium binding resulting in the exposure
of the hydrophobic binding sites which then allows other target
proteins to bind to CaM [15]. Recently, it has been shown that
CaM binds and regulates the function and activity of several
small GTPases [17–20].
In the present study, we demonstrate that CaM associates with
Rac1 and Cdc42 and this interaction was confirmed in platelets
using co-immunoprecipitation studies. Treatment of human
platelets with thrombin resulted in the activation of Rac1 and
Cdc42. Incubation with W7 prior to the addition of thrombin
resulted in inhibition of Rac1 activation. However, incubation of
platelets with W7 or W7 plus thrombin resulted in the activation
of Cdc42. The results demonstrate a role for CaM in the acti-
vation of Rac1 and Cdc42 and thus, in controlling cell morphol-
ogy and cytoskeleton rearrangement.
2. Materials and methods
2.1. Reagents and plasmids
Sepharose 4B coupled CaM was purchased from Amersham Biosciences.
Monoclonal Rac1 and Cdc42 antibodies were obtained from BD Transduction
Laboratories. Monoclonal CaM antibody was obtained from Upstate Bio-
technologies. Monoclonal Cdc42 immunoprecipitation-positive antibody and
protein A/G PLUS agarose beads were purchased from Santa Cruz Biotechnol-
ogy. Thrombin, glutathione–agarose and actin rabbit polyclonal antibody were
purchased from Sigma. Bovine brain CaM, W7•HCl and W5•HCl were pur-
chased from Calbiochem. Control mouse IgG1 was purchased from MediCrop
Inc. Triton X-100, BSA standard and Bio-Rad protein assay dye reagent were
purchased from Bio-Rad Laboratories. The predicted Rac1 CaM-binding peptide
(NH2–AVKYLECSALTQRG–COOH) and the scrambled form of this peptide
(NH2–TEGAYACKSLQLVR–COOH) were custom synthesized by Sigma
Genosys. All other reagents were from Sigma except where indicated. GST-
Rac1 and GST-Cdc42, and GST-Pak1 bacterial expression plasmids were kindly
provided by Dr. R. Weinberg and Dr. M. Hoshino respectively.
2.2. Isolation of GST fusion protein
GST and the recombinant GST fusion proteins, GST-Rac1, GST-Cdc42 and
GST-Pak1, were expressed in Escherichia coli and purified using glutathione–
agarose beads as described previously [21]. The purity of the final preparations
was assessed using SDS-PAGE.
2.3. Preparation of human platelets
Blood was collected into acid citrate dextrose anti-coagulant (3.8 mM citric
acid, 7.5 mM trisodium citrate, 125 mM dextrose; 3.6 mL anti-coagulant/20 mL
whole blood) by venipuncture of human volunteers who had denied taking
medication known to interfere with platelet function within the previous 2 weeks.
Platelet-rich plasma was obtained by centrifugation at 600 ×g for 20 min at roomtemperature. The supernatant containing the purified platelets was centrifuged at
1000 ×g for 15 min at room temperature, and the resultant platelet pellet was
resuspended in HEPES/Tyrode buffer (10 mM HEPES, pH 7.4, 137 mM NaCl,
2.68 mM KCl, 0.42 mM NaH2PO4, 1.7 mM MgCl2 and 5 mM Glucose). The
platelets were allowed to equilibrate for 30 min at 37 °C prior to being used in
experiment. Platelet studies were approved by the Human Research Ethics Board
of the University of Manitoba and informed consent was obtained from all the
volunteers.
2.4. CaM-Sepharose pull-down of Rac1 and Cdc42 from platelet lysate
Fresh isolated human platelets were lysed for 30 min at 4 °C in CaM-binding
buffer containing 20 mM HEPES, pH 7.4, 200 mM KCl, 1 mM MgCl2, 0.55%
Triton X-100 and a protease inhibitor cocktail consisting of 200 mM benza-
midine, 2 μg/μl aprotinin, 83.4 mM AEBSF, 5 μg/μl leupeptin, and 0.025 mM
pepstatin A. The lysate was centrifuged at 14,000 ×g for 10 min at 4 °C. After
centrifugation, platelet supernatant (∼2 mg) was incubated with 100 μl of CaM-
Sepharose 4B beads (3:1 ratio of settled gel to buffer) that were previously
equilibrated in CaM-binding buffer. Treatment conditions included: buffer,
buffer plus 10 mM EGTA, buffer containing 5 mM Ca2+, buffer containing
10 mM EGTA plus variable Ca2+ concentrations (1 mM Ca2+, 3 mM Ca2+ or
5 mM Ca2+). Blank Sepharose 4B beads (100 μl) were used as control. The
reaction mixture was incubated for 2 h at 4 °C. Unbound proteins were removed
by washing three times in CaM-binding buffer. Laemmli's sample buffer [22]
was added to washed beads and heated at 100 °C for 5 min. Eluted proteins were
subjected to 12% SDS-PAGE, electrophoretically transferred to PVDF
membranes, and Western blotting was performed with anti-Rac1 or anti-Cdc42
(1 μg/ml) antibodies and horse-radish peroxidase (HRP)-conjugated secondary
goat anti-mouse antibody (1:5000 dilution). The antigen–antibody complex was
detected using enhanced chemiluminescence (ECL) reagents.
2.5. GST-Rac1 and GST-Cdc42 interaction with pure CaM
PurifiedGSTor GST-Rac1 or GST-Cdc42 bound to GSH-agarose beads were
washed with MOPS buffer consisting of 30 mMMOPS, pH 7.2, 1% NP-40 and
100 mM KCl. In addition to buffer alone, 10 mM EGTA, 5 mM Ca2+, or 10 mM
EGTA plus different Ca2+ concentrations (1 mM Ca2+, 3 mM Ca2+, 5 mM Ca2+)
plus 20 μg of pure CaM were added to tubes containing GST or GST-Rac1 or
GST-Cdc42 (100 μl) and allowed to shake for 2 h at 4 °C. After incubation, the
beads were washed three times with MOPS buffer containing the appropriate
concentration of Ca2+ and/or EGTA. Laemmli's sample buffer was added to
washed beads and heated at 100 °C for 5 min. Western blotting was performed
using anti CaM (1 μg/ml) antibody and the antigen–antibody complex was
visualized using ECL.
2.6. Coupling of Rac1 CaM-binding and scrambled peptides to
CNBr-activated Sepharose beads
The potential CaM-binding and scrambled peptides from Rac1 were coupled
to CNBr-activated Sepharose beads according to the manufacturer's instructions.
Briefly, peptide (2.5 mg/ml) was dissolved in 1× PBS and mixed 0.5:1 v/v with
0.1–0.3 g of CNBr-activated Sepharose beads that had beenwashed in 1mMHCl
(15 times bead volume) and a final wash in PBS. The mixture was gently rocked
overnight at 4 °C. The beads were pelleted, the supernatant decanted, 1.0 ml of
10mMTris–HCl, pH 7.5, was added and themixture rocked gently at 4 °C for 3 h
to block empty sites on the beads. The beads were pelleted and washed in 1.0 ml
of 10 mM Tris–HCl, pH 8–9, followed by washing in 1.0 ml of 100 mM acetate
buffer, pH 4.0. This washing process was repeated 5 times, after which the beads
were recovered and stored in 20% ethanol at 4 °C until needed for experiment.
Blocked CNBr-activated Sepharose beads were used as a control in these
experiments.
2.7. In vitro binding assays
Rac1 CaM-binding peptide or scrambled version of the peptide coupled to
CNBr-activated Sepharose beads was incubated with 20 μg of pure CaM or
platelet lysate (~2 mg) in Buffer B (50 mM Tris–HCl, pH7.5, 10% Glycerol,
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Blocked CNBr-Sepharose beads were used to assess non-specific binding of
CaM. After the incubation, beads were collected by centrifugation and unbound
proteins removed by washing three times in Buffer B. Laemmli's sample buffer
(30 μl) was added to beads and heated at 100 °C for 5 min. Western blotting was
performed using anti-CaM (1 μg/ml) antibodies and the antigen–antibody
complex was visualized using ECL.
2.8. In vitro competition assay
To assess if the peptide inhibits Rac1 binding to CaM, CaM-Sepharose beads
(100 μl) were incubated with different concentrations of free peptide (0 μM,
250 μM, 500 μM, 750 μM, 1000 μM) and rocked gently for 2 h in CaM-binding
buffer (20mMHEPES, pH 7.4, 200mMKCl, 1mMMgCl2, 0.55%TritonX-100
and a protease inhibitor cocktail consisting of 200 mM benzamidine, 2 μg/μl
aprotinin, 83.4 mMAEBSF, 5 μg/μl leupeptin, and 0.025 mM pepstatin A). The
supernatant was decanted and beads were washed oncewith CaM-binding buffer.
Platelets were lysed in CaM-binding buffer containing a protease inhibitor
cocktail. The lysate was centrifuged at 14,000 ×g for 10 min. The platelet
supernatant (∼2 mg) was added to washed beads and rocked gently for 2 h at
4 °C. Blank Sepharose 4B beads (100 μl) were used as control. Unbound proteins
were removed by washing three times in CaM-binding buffer. Laemmli's sample
buffer (30 μl) was added to washed beads and heated at 100 °C for 5min.Western
blotting was performed using anti-Rac1 (1 μg/ml) antibody and the antigen–
antibody complex was detected using ECL.
2.9. Immunoprecipitation of CaM-Rac1 and CaM-Cdc42 complex from
platelets
Fresh human platelets were lysed in Triton lysis buffer (50 mM Tris, pH 7.2,
1% Triton X-100, 10 mMEGTA, 1 mMNa2VO4) containing a protease inhibitor
cocktail tablet (Roche Diagnostics). The lysates were clarified by centrifugation
(14,000 ×g for 10min), and the supernatants (∼1mg)were pre-cleared by adding
30 µl of protein A/G Plus-agarose beads for 2 h at 4 °C. After centrifugation, the
supernatant (~2 mg) was pre-cleared with 4 µg/ml of control mouse IgG1 prior to
incubation for 3 h at 4 °C with 4.0 µg/ml of mouse anti-Rac1 or 4.0 µg/ml of
mouse anti-Cdc42 monoclonal antibodies or 4 µg/ml of control mouse IgG1.
Protein A/G Plus-agarose beads (30 µl) were added to the mixture and rocked at
4 °C for 1 h. The beads were collected by centrifugation (16,000 ×g for 25 s) and
washed four times in Triton lysis buffer minus detergent (50 mM Tris, pH 7.2,
10 mM EGTA, and 1 mM Na2VO4). The beads were resuspended in 20 µl of
Laemmli's sample buffer and heated for 5 min at 100 °C. Western blotting was
performed using anti-CaM (1 µg/ml) antibody and the antigen–antibody com-
plex was detected using ECL.
2.10. Rac1 and Cdc42 activation assay in platelets
Platelets were purified as described previously and challenged with thrombin
(1 U/ml) for different periods to determine optimal time-points for Rac1 and
Cdc42 activation. Having determined the optimal time-point for Rac1 and Cdc42
activation, platelets were stimulated for the appropriate time using the following
conditions: no addition, thrombin (1 U/ml), W7 (150 μM), W7 (150 μM) plus
thrombin (1 U/ml),W5 (150 μM),W5 (150 μM) plus thrombin (1 U/ml). Platelets
were incubated for 5 min with W7 or W5 prior to addition of thrombin. Platelets
were lysed using RIPA buffer (50 mM Tris, pH 7.4, 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS, 500 mMNaCl, 10 mMMgCl2, 2.5 mMEGTA,
and a protease inhibitor cocktail) and shaken for 30 min at 4 °C. The lysate was
centrifuged at 14,000 ×g at 4 °C. After centrifugation, the supernatant (∼2 mg)
was transferred into a separate tube and stored immediately on ice. The amount of
activated Rac1 or Cdc42 in platelet lysate was determined using GST-Pak1. Thus,
the centrifuged platelet lysate was incubated with GST-Pak1 coupled to GSH-
agarose beads (100 μl) at 4 °C for 2 h. After incubation, the beads were washed
three times with cold Rac1–Cdc42 washing buffer (50 mM Tris–HCl, pH 7.4,
10 mM MgCl2, 150 mM NaCl, 1% Triton X-100, 5 mM EGTA, and a protease
inhibitor cocktail). The final bead pellet was suspended in 30 μl of Laemmli's
sample buffer and heated at 100 °C for 5 min. Western blotting was performedusing mouse anti-Rac1 or anti-Cdc42 monoclonal antibodies (1 μg/ml) and the
antigen–antibody complex detected using ECL.
2.11. W7 and W5 competition assay
To assess if W7 can inhibit CaM interaction with Rac1 and Cdc42 we
employed an in vitro assay. Platelets were purified as described above and lysed
using RIPA buffer (50 mM Tris, pH 7.4, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 500 mM NaCl, 10 mMMgCl2, 2.5 mM EGTA, and a
protease inhibitor cocktail) and shaken for 30 min at 4 °C. The lysate was
centrifuged at 14,000 ×g at 4 °C. After centrifugation, the supernatant (∼2 mg)
was transferred into a separate tube and stored immediately on ice. The platelet
cell lysate was then pre-incubatedwithW7 (150μM) orW5 (150μM) for 15min.
At the end of this incubation. the platelet lysate were further incubated with GST-
Rac1 or GST-Cdc42 coupled to GSH-agarose beads (150 μl) at 4 °C for 2 h.
Platelet cell lysate incubated with GST-Rac1 (150 μl) or GST-Cdc42 (150 μl)
beads without the addition of W7 or W5 were used as control. After incubation,
the beads were washed three times with cold RIPA buffer with the protease
inhibitor cocktail. The final bead pellet was suspended in 30 μl of Laemmli's
sample buffer and heated at 100 °C for 5 min. Western blotting was performed
using anti-CaM antibodies (1 μg/ml) and the antigen–antibody complex was
detected using ECL.
2.12. Calcium concentration determinations
Calcium concentration in the buffer containing no exogenous calcium or
EGTAwas determined by measuring total calcium ions using atomic absorption
spectrophotometry [18]. Free calcium concentrations in buffers containing
10 mM EGTA and different amounts of exogenous calcium were calculated
using the MAXCHELATOR software (www.stanford.edu/~cpatton/maxc.html).
2.13. Protein determination
Total protein concentration in lysates was determined using Bio-Rad dye
reagent (Bio-Rad laboratories). The absorbance at 595 (A595) was measured and
compared to a standard curve of known protein BSA concentrations.
2.14. Statistical analysis
Where required the autoradiograph was scanned and bands quantified using
Bio-Rad “Quantity One” program. The output was normalized and descriptive
statistical analysis and t-tests were performed.3. Results
3.1. Endogenous Rac1 and Cdc42 interact with CaM-Sepharose
To determine if Rac1/Cdc42 and CaM interact, and assess the
Ca2+ dependence of such,CaM-Sepharose beads pull down assays
were used. Results demonstrated that endogenous Rac1 (Fig. 1A)
and Cdc42 (Fig. 1B) interact with CaM. There was no binding of
endogenous Rac1 and Cdc42 to blank Sepharose beads (Fig. 1A
and B). Quantification of the data confirmed that the interaction
between Rac1 and CaM showed Ca2+-dependency since addition
of 10 mM EGTA almost eliminated binding and addition of
increasing concentration of Ca2+ in the presence of 10 mMEGTA
significantly enhanced the binding of CaM to Rac1 (Fig. 1A). A
similar pattern was observed for the binding of Cdc42 to CaM
(Fig. 1B).As indicated in the figure, the free calcium concentration
in the various samples was within the physiological range. The
lysates in various experimental samples contained equal amount
of protein as determined using actin antibody (Fig. 1C).
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To establish if Rac1 and Cdc42 bind directly to CaM, we
used GST-Rac1 and GST-Cdc42 fusion proteins and pure
bovine brain CaM in in vitro binding assays. The expression of
both GST-Rac1 and GST-Cdc42 in E. coli was assessed prior to
performing experiments. The pure recombinant proteins
demonstrated the expected molecular mass on SDS-PAGE
gel. The recombinant proteins were then used to assess if Rac1
and Cdc42 interact directly with CaM. The results demonstratedFig. 2. GST-Rac1 and GST-Cdc42 bind to purified bovine brain CaM. GST-Rac1
(A) or GST-Cdc42 (B) beadswere incubatedwith purified CaM (20 μg) inMOPS
buffer (30 mM MOPS pH 7.2, 1% NP-40, and 100 mM KCl) and allowed to
shake for 2 h at 4 °C. GST beads were used as negative control. The incubation
conditions included GST-Rac1 (A) or GST-Cdc42 (B) beads with buffer alone,
buffer plus 10mMEGTA, buffer plus 5mMCa2+, buffer with 10mMEGTA plus
varying Ca2+ concentrations (1 mM, 3 mM and 5 mM). The calculated free Ca2+
concentration in various treatments are shown in brackets in the figure above. At
the end of the incubation, beads were washed and bound proteins eluted using
Laemmli's sample buffer. Western blot analysis was carried out using anti-CaM
monoclonal antibodies. Quantification was carried out using Bio-Rad “Quantity
One” program and the values (mean±S.E.M.) were considered significantly
different when p values were b0.05 compared with the 10 mM EGTA samples
(⁎) (n≥3).
Fig. 1. Endogenous Rac1 and Cdc42 interact with CaM-Sepharose. To establish
Rac1 and Cdc42 interaction with CaM and determine its Ca2+ dependence, CaM-
Sepharose 4B beads (100 μl) were incubated with platelet lysate (~2 mg) for 2 h
at 4 °C in buffer alone, in buffer containing 10 mM EGTA, in buffer containing
5 mM Ca2+, and in buffer containing 10 mM EGTA plus differing Ca2+ con-
centrations (1 mM, 3 mM and 5 mM). The calculated free Ca2+ concentration in
various treatments are shown in brackets in the figure above. At the end of the
incubation, beads were washed and bound proteins eluted using Laemmli's
sample buffer. Western blot analysis was carried out using anti-Rac1 (A) or anti-
Cdc42 (B) antibodies. Equal amount of protein in the starting platelet lysates was
confirmed in (C) by probing for actin. Sepharose 4B beads (100 μl) were used
to assess non-specific binding. Quantification was carried out using Bio-Rad
“Quantity One” program and the values (mean±S.E.M.) were considered sig-
nificantly different when p values were b0.05 compared with the 10 mM EGTA
samples (⁎) (n≥3).that pure CaM indeed binds specifically to Rac1 and Cdc42
(Fig. 2A and B). Quantification of the data confirmed that CaM
binding demonstrated Ca2+-dependency as an increase in free
Ca2+ concentration (indicated in brackets in the figure)
significantly enhanced the binding of CaM to both Rac1 (Fig.
2A) and Cdc42 (Fig. 2B). There was no binding of CaM
observed to GSH-agarose beads containing bound GST (Fig.
2A and B). These results confirm that CaM directly interacts
with Rac1 and Cdc42.
3.3. Determination of potential CaM-binding site in Rac1
Since we demonstrated that CaM binds directly to Rac1, we
next screened the Rac1 sequence for potential CaM-binding do-
mains using theCaM target database [23]. The database revealed a
Fig. 3. CaM-binding peptide from Rac1 binds endogenous and pure CaM. CaM-
binding peptide (AVKYLECSALTQRG) from Rac1 or scrambled version of the
peptide (TEGAYACKSLQLVR) were covalently coupled to CNBr-activated
Sepharose beads as described in “Materials and methods”. The beads (50 µl or
100 µl) containing Rac1 CaM-binding peptide were incubated with platelet
lysate (A) or pure CaM (B) and the scrambled peptide (50 µl or 100 µl) coupled
to beads was incubated with platelet lysate (C) for 2 h or 24 h at 4 °C. After
washing, proteins bound to beads were separated by SDS-PAGE and Western
blotting performed using antibodies against CaM. Blocked empty Sepharose
beads (100 µl) were used for determining non-specific binding. A representative
autoradiograph is shown above but the experiment was repeated a minimum of
three times with consistent results.
Fig. 4. Free peptide competes with endogenous Rac1 for binding to CaM-
Sepharose beads and, CaM-Rac1 and CaM-Cdc42 coprecipitate from platelet
cell lysate. CaM-Sepharose beads were used to establish whether Rac1 binding
to these beads is inhibited by the Rac1 CaM-binding peptide. (A) CaM-
Sepharose beads were incubated with 0, 250, 500, 750, or 1000 μM of peptide
for 2 h, washed to remove free peptide and incubated with platelet lysates for 2 h
at 4 °C. After washing, proteins bound to beads were separated by SDS-PAGE
and Western blotting was performed using antibodies against Rac1. (B) For
immunoprecipitation, platelets were lysed using Triton X-100 buffer and
prepared for Co-IP as described under “Materials and methods”. Briefly, platelet
lysates were incubated with anti-Rac1 or anti-Cdc42 monoclonal antibodies or
with mouse IgG1 antibody. The antigen–antibody complex was isolated using
protein A/G Plus-Agarose beads. The immunoprecipitated proteins were
separated by 12% SDS-PAGE and probed with anti-CaM antibodies. In the
case of (A) and (B), quantification was carried out using Bio-Rad “Quantity
Onee” program. The values (mean±S.E.M.) were considered significantly
different when p values were b0.05 compared with (A) Rac1 binding in the
absence of exogenous peptide and (B) non-specific CaM in IgG1 immunopre-
cipitate samples (⁎) (n≥3).
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cated in the C-terminal of Rac1. CaM binding to target proteins
can be calcium-dependent or -independent [15]. The typical CaM-
binding regions vary in length between 16–30 amino acids. They
also have tendency to form amphipathic α-helices with a hydro-
phobic and a basic face [24,25]. The proposed 14 amino acidRac1
CaM-binding sequence [AVKYLECSALTQRG] is composed of
57.14% hydrophobic and 42.86% hydrophilic residues [25]. This
region of Rac1 has an alanine and a glycine residue at each end,
which are weak hydrophobic amino acids and are characteristic
of CaM-binding motifs. It is not a CaM-binding IQ motif since
it does not comply with the IQ motif sequence [IVL]Qxxx[RK]
xxxxx[RK] where X is any amino acid. A similar CaM-binding
site in Cdc42 [AVKYVECSALTQK] that is composed of 53.85%
hydrophobic and 46.15%hydrophilic residueswas also identified.
3.4. Rac1 CaM-binding peptide interacts with endogenous and
pure CaM
To assess whether the synthesized Rac1 peptide [AVKYLEC-
SALTQRG] binds CaM, we coupled it to CNBr-activated
Sepharose beads.We used a direct approach in which the coupled
peptide was added to platelet cell lysate to examine binding to
endogenous CaM. The results demonstrate that there was no
binding observed when blocked CNBr-Sepharose beads (100 μl)were used with platelet lysate (Fig. 3A). But binding was ob-
served when coupled peptide was used (Fig. 3A). Higher binding
was observed in platelet lysate incubated for 2 h with the peptide
(Fig. 3A). The opposite approach in which coupled peptide was
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peptide binds pure CaM (Fig. 3B). The scrambled version of the
Rac1 CaM-binding peptide [TEGAYACKSLQLVR] failed to
demonstrate any interaction with CaM (Fig. 3C). These resultsFig. 5. Time-course for activation of platelet Rac1 and Cdc42. Freshly drawn
human platelets were prepared as described under “Materials and methods”,
divided into 500 μl aliquots and incubated for 30 min at 37 °C prior to thrombin
treatment (1 U/ml) for the indicated times. After thrombin treatment, the platelets
were lysed in RIPA buffer and incubatedwith 100 μl of GST-Pak1 beads for 2 h at
4 °C to recover GTP-bound Rac1 or GTP-bound Cdc42. The beads were washed
three times with Rac1 or Cdc42 washing buffer. Bound proteins were eluted
using Laemmli's sample buffer and Rac1-GTP or Cdc42-GTP was detected by
Western blotting using a monoclonal antibody against Rac1 (A) or Cdc42 (B).
Part (C) represents confirmation of equal amount of protein in the starting lysates
as demonstrated by probing for actin. The blots shown are a representative
autoradiograph from experiments repeated two times with consistent results. The
data was quantified using Bio-Rad “Quantity One” program. The time-point of
maximal activation was taken as 100%.
Fig. 6. CaM is required for thrombin-induced activation of platelet Rac1.
Freshly drawn human platelets were prepared as described under “Materials and
methods”, divided into 500 μl aliquots and incubated for 30 min at 37 °C prior to
thrombin treatment (1 U/ml). Five minutes before thrombin addition, the
indicated aliquots were treated with 150 μM of CaM inhibitor W7 or 150 μM of
W5. After thrombin treatment for 1 min, the platelets were lysed in RIPA buffer
and incubated with 100 μl of GST-Pak1 beads for 2 h at 4 °C to recover GTP-
bound Rac1. After washing, proteins bound to beads were eluted using
Laemmli's sample buffer and Rac1-GTP detected by Western blotting using a
monoclonal antibody against Rac1. Quantification was carried out using Bio-
Rad “Quantity One” program and the values (mean±S.E.M.) were considered
significantly different when p values were b0.05 compared with the control or
thrombin samples (⁎) (n≥3). The experiment was repeated a minimum of three
times using blood from three different donors.confirm that Rac1 CaM-binding peptide interacts directly and
specifically with CaM.
3.5. Rac1 CaM-binding peptide competes with Rac1 for binding
to CaM-Sepharose
To determine whether the proposed Rac1 CaM-binding pep-
tide competes for binding to CaM, we used CaM-Sepharose
beads as a tool. CaM-Sepharose beads were incubated with
different concentrations of free peptide for 2 h prior to incubation
with platelet lysate (Fig. 4A). Quantification of results demon-
strated a significant decrease in Rac1 binding to CaM-Sepharose
beads as the concentration of free CaM-binding peptide added
was increased (Fig. 4A). Blank Sepharose beads did not inter-
act with Rac1 (Fig. 4A). This confirms that the exogenous
Rac1 CaM-binding peptide is interacting with CaM bound to
Sepharose beads thus making CaM unavailable for binding to
Rac1 from platelet lysate.
3.6. Rac1 and Cdc42 are associated with CaM in platelets
Co-immunoprecipitation experiments were performed to estab-
lishwhether endogenous Rac1 andCdc42 are associatedwithCaM
in platelets. CaM coprecipitated from platelet extracts with anti-
Rac1 and anti-Cdc42 (Fig. 4B). Quantification of data confirmed
that significantly higher level of CaM was immunoprecipitated
with anti-Rac1 or anti-Cdc42 antibodies than with control IgG1
(Fig. 4B). The co-immunoprecipitation data provides further
evidence that Rac1 and Cdc42 interact with CaM in platelets.
Fig. 7. CaM inhibits platelet Cdc42 GTPase activity. Freshly drawn human
platelets were prepared as described under “Materials andmethods”, divided into
500 μl aliquots and incubated for 30 min at 37 °C prior to thrombin treatment
(1 U/ml). Five minutes before thrombin treatment, the indicated aliquots were
treated with 150 μM of CaM inhibitor W7 or 150 μM of W5. After thrombin
treatment for 25 s, the platelets were lysed in RIPA buffer and incubated with
100 μl of GST-Pak1 beads for 2 h at 4 °C to recover GTP-bound Cdc42. The
beads were washed three times with Cdc42 washing buffer. Bound proteins were
eluted using Laemmli's sample buffer and Cdc42-GTP detected by Western
blotting using a monoclonal antibody against Cdc42. Quantification was carried
out using Bio-Rad “Quantity One” program and the values (mean±S.E.M.) were
considered significantly different when p values were b0.05 compared with the
control or thrombin samples (⁎) (n≥3). The experiment was repeated aminimum
of three times using blood from three different donors.
Fig. 8. W7 inhibits CaM binding to Rac1 and Cdc42. Freshly drawn human
platelets were prepared and lysed in RIPA buffer as described under “Materials
and methods”. 500 μl aliquots of the lysate were incubated with 150 μM of CaM
inhibitor W7 or 150 μM of W5 for 15 min. After the incubation, (A) GST-Rac1
(150 μl) or (B) GST-Cdc42 beads (150 μl) were added and incubated for 2 h at
4 °C. After centrifugation, the beads were washed three times with RIPA buffer
and CaM detected by Western blotting using a monoclonal antibody against
CaM.Quantification was carried out using Bio-Rad “Quantity One” program and
the values (mean±S.E.M.) were considered significantly different when p values
were b0.05 compared with the control sample (⁎) (n≥3).
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We have previously shown that CaM is required for the
activation of RalA and RalB in human platelets [17]. Thus,
to assess a potential role of CaM in the activation of Rac1 and
Cdc42,we used human platelets as themodel cell system.We used
the p-21 activated kinase (Pak) to determine the level of Rac1-
GTP and Cdc42-GTP in cells. The p-21 activated kinase (Pak) is a
downstream target of Rac1 and Cdc42, and interacts specifically
with the GTP-bound form of both Rac1 and Cdc42 [26–28]. This
feature of Pak has been exploited to determine the level of active
Rac1 and Cdc42 in cells [27–29]. Thus, initially we used GST–
Pak1 (expressing the Rac1 and Cdc42 binding domain of Pak1
coupled to the GST protein) fusion protein to confirm that it only
interacts with the Rac1-GTP and Cdc42-GTP forms in platelets
(results not shown). Expression and purification of recombinant
GST–Pak1 in E. coli was assessed using SDS-PAGE.
To determine if CaM is involved in activation of Rac1 and
Cdc42, we initially confirmed the optimal time-point for Rac1
and Cdc42 activation using the known agonist, thrombin.
Thrombin has been shown to activate platelet Rac1 and Cdc42
[27,28]. We used GST–Pak1 fusion protein to pull down the
active form of Rac1 and Cdc42 from platelets at different time-
points. The optimal time-point for Rac1 and Cdc42 was deter-
mined to be 60 s and 25 s, respectively (Fig. 5A and B), and this
is consistent with data previously reported by others [27,28].
Equal amounts of protein were present in the various samples
(Fig. 5C).3.8. CaMactivates Rac1 and inhibits Cdc42 activation in platelets
Having established the optimal time-point for Rac1 andCdc42
activation, we next investigated the role of CaM in Rac1 and
Cdc42 activation in platelets. Thrombin caused an approximately
two fold increase in the activation of Rac1 (Fig. 6). This
thrombin-induced activation was abolished in the presence of the
CaM inhibitor, W7, but was not affected to the same extent in the
presence of the less potent CaM inhibitor, W5 (Fig. 6). In case of
Cdc42, thrombin caused a 1.5-fold increase in Cdc42 activation
in human platelets (Fig. 7). Addition of W7 alone to platelets
resulted in a significant increase in theGTP-bound form ofCdc42
and this was further enhanced in the presence of thrombin plus
W7 (Fig. 7). W5 did not result in activation of Cdc42 (Fig. 7).
These results suggest that CaM has opposing effects on the
activation process of Rac1 and Cdc42. In case of Rac1, CaM is
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Cdc42 activation since addition of W7 resulted in activation of
Cdc42.
To confirm that W7 inhibits interaction of CaM with Rac1
and Cdc42, we used an in vitro binding assay. The results
demonstrated that W7 significantly inhibits the interaction be-
tween CaM and Rac1 (Fig. 8A) and CaM and Cdc42 (Fig. 8B).
The less potent CaM inhibitor, W5, did not affect these inter-
actions (Fig. 8A and B).
5. Discussion
In response to an increase in intracellular Ca2+ concentration,
CaM undergoes a conformational change that allows it to
interact with its target proteins and modify their function. Thus,
CaM and CaM-binding proteins play an important role in
intracellular Ca2+ signaling and in various physiological func-
tions including glycogen metabolism, secretion, muscle con-
traction, actin/cytoskeletal organization and cell division [30]. It
has been shown that epidermal growth factor induced Ca2+
influx is mediated by Rac proteins [31] and that CaM antagonists
block the activation of small GTPases Rac1 and Ras in neutro-
phils [32]. However, the mechanism by which CaM regulates
Rac1 GTPase activity is not understood. In addition, it is not
known if other members of the Rho family of small GTPases (for
example, Cdc42) are also regulated by CaM. The fact that CaM
has been shown to interact and regulate the activation of several
small GTPases [17–20] led us to test the hypothesis that CaM
interacts and regulates the activity of GTPases belonging to the
Rho family.
We have found a novel interaction between the small GTPases
Rac1, Cdc42 and CaM. This interaction was found to be direct
and occurs at low levels of calcium and is increased at higher
calcium concentrations. The free calcium concentration used in
our in vitro study is in the physiological range suggesting that
this interaction is likely to occur in cells. The interaction of CaM
with Rac1 or Cdc42 was further confirmed in platelets using co-
immunoprecipitation. The results from co-immunoprecipitation
studies confirmed that CaM is associated with these GTPases in
platelets (Fig. 4B).
CaM has been shown to interact with a variety of small
GTPases [17–20]. Thus, CaM binds to RalA and RalB and is
necessary for the thrombin-mediated activation of these GTPases
in platelets [17]. It has also been shown that CaM can promote
GTP-GDP exchange on RalA [33]. CaM also causes dissociation
of RalA from synaptic vesicle membranes in a Ca2+-dependent
fashion [33]. Similar regulatory mechanisms have been reported
for K-RasB [35], Rab3A [34] and Rab3B [18]. The interaction of
CaM with its target proteins is predominantly hydrophobic and
strong electrostatic interactions [20]. The proposed Rac1 CaM-
binding peptide identified by us is located within amino acids
151–164 in the C-terminal of Rac1. This region is composed
mostly of hydrophobic amino acid residues and can potentially
serve as the CaM-binding site in Rac1. The Rac1 CaM-binding
peptide was indeed able to bind endogenous (Fig. 3A) and pure
CaM (Fig. 3B)while the scrambled version of the peptide failed to
interact with CaM (Fig. 3C). Moreover, the peptide was able toinhibit binding of Rac1 to CaM (Fig. 4A). Further studies are
required to confirm that in the full-length version of Rac1 this
region is responsible for binding CaM. A similar CaM-binding
region is present in Cdc42 but its ability to interact with CaM has
not yet been confirmed.
In platelets, Rac1 and Cdc42 activation occurs after stimu-
lation of G-coupled PAR-1 by thrombin [27]. The optimal time-
points for Rac1 and Cdc42 activation by thrombin were re-
examined in platelets and determined to be 60 s and 25 s,
respectively (Fig. 5A and B). These results are similar to those
reported by other investigators previously for optimal platelet
Rac1 [27] and Cdc42 [28] activation in response to thrombin.
The role of CaM in Rac1 and Cdc42 function was examined
using platelet as our model system at the optimal time-point for
activation of Rac1 and Cdc42. Previously it has been shown that
the CaM inhibitor W7 inhibits the activation of Rac1 in neutro-
phils [32]. Similar results were obtained in our studies with
platelets (Fig. 6). The addition of thrombin after pretreatment
with W7 did not reverse the inhibitory effects of W7 on Rac1
activation. This suggests a role for CaM in Rac1 activation. In
contrast, amount of active Cdc42 was significantly increased
after the addition of W7 and a further increase was observed
upon the addition of W7 plus thrombin (Fig. 7). The less potent
CaM inhibitor, W5, had little effect on Rac1 and Cdc42 acti-
vation (Fig. 6 and 7). This implies that CaM in platelets acts to
maintain Cdc42 in the inactive state. A similar type of inhibitory
role for CaM has been described in the case of K-RasB [35].
Furthermore, we have shown that in comparison to W5, W7 is
much more effective in disrupting CaM interaction with Rac1
and Cdc42 (Fig. 8). The present results suggest that CaM is
important in coordinating the activation of Rac1 and Cdc42 in
platelets. The reason for the opposite effect of CaM on Rac1 and
Cdc42 function is not clear and it is unknown at the present time
if a similar mechanism exists in cell types other than platelets.
The real-time visualization of Rac1 and Cdc42 activation in
platelets or another cell type may help in confirming the role
CaM in the activation step of these GTPases.
Rac1 is known to regulate membrane ruffles (lamellapodia)
through formation of cortical actin fibers [1,2,5] and, Cdc42 is
implicated in filopodia formation and in cell migration [4,5,36].
This type of cytoskeletal rearrangement is the hallmark during
platelet activation step. HowCaM participates in these pathways
through its ability to regulate Rac1 and Cdc42 activation is not
clear. However, CaM has been reported to act as a GEF for the
Ral GTPase [37]. Thus, it is possible that CaM may play a
similar role in controlling Rac1 and Cdc42 activation. It will be
important to confirm the precise region within Rac1, Cdc42 that
interacts with CaM and, how these novel interactions impact
platelet physiology.
In conclusion, we have shown in the present study that the
calcium sensor protein, CaM, interacts with and regulates the
activity of small GTPases Rac1 and Cdc42. This interaction was
found to occur within the physiological range of intracellular
Ca2+-concentration. The binding of CaM to Rac1 increases
its activation in cells while its binding to Cdc42 inhibits the
activation of this GTPase. Further, using a synthetic peptide
representing the CaM-binding region in Rac1, we have
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confirmed this novel interaction in cells using co-immunopre-
cipitation. The opposing effects of Ca2+/CaM on the activation
of Rac1 and Cdc42 suggests a complex mechanism for the
coordination of the function of these GTPases in the cell and
provides a link between Ca2+/CaM and changes in cell morphol-
ogy and cytoskeleton dynamics.
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